Immuron (IMRN) Stock: Buy, Sell, or Hold?
IMRN - Immuron Limited American Depositary Shares
$1.45
-0.18 (-11.04%)
▼
5d:
+30.63%
30d:
+31.76%
90d:
+16.94%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 27, 2026
0d
Get Alerted When IMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IMRN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IMRN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMRN is currently trading at $1.45, which is considered extended relative to its 30-day fair value range of $0.99 to $1.46.
Technical Outlook: Technically, IMRN is in a uptrend. Immediate support is located at $1.06, while resistance sits at $1.99. Short-term momentum is weak, with the stock down 11.0% recently.
Market Sentiment: IMRN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.01 (+176.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMRN is in a uptrend. Immediate support is located at $1.06, while resistance sits at $1.99. Short-term momentum is weak, with the stock down 11.0% recently.
Market Sentiment: IMRN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.01 (+176.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.99 -
$1.46
Company Quality Score
34/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BEARISH: Downward momentum (-11.0%)
- BULLISH: Trading 176.5% below Wall St target ($4.01)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.99 -
$1.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.99
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-96.03
Wall Street Target
$4.01
(+176.5%)
Revenue Growth (YoY)
7.2%
Profit Margin
-49.8%
Share & Embed Analysis
Last updated: September 13, 2026 6:09 AM ET
Data refreshes hourly during market hours. Next update: 7:09 AM
Data refreshes hourly during market hours. Next update: 7:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
